Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BYMedComm

Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate-to-Severe Atopic Dermatitis: A Phase IV, Non-Randomized, Open-Label, Parallel-Group Clinical Study.

  • Taoming Liu1,2
  • Shuting Chen1,2,3
  • Weijia Zhao3,2
  • Dake Di4
  • Jiao Liu2
  • Yuyang Tian3,2
  • Yurong Luo3,2
  • Yingping Xu5
  • Ruzeng Xue2
  • Li Ye6
  • Xiaoping Pei2
  • Bihui Yu2
10 more authors
  • Yu Wang2
  • Jiao Zhang2
  • Xiaoling Yu2
  • Wei Wen2
  • Liyan Yuan2
  • Suyun Ji2
  • Claire Hu7
  • Dan Shen8
  • Yiqing Guo9
  • Yunsheng Liang1,2,10
10 affiliations
  1. 1Hunan Key Laboratory of Medical Epigenomics The Second Xiangya Hospital of Central South University Changsha China.
  2. 2Department of Dermatology Dermatology Hospital Southern Medical University Guangzhou China.
  3. 3The First School of Clinical Medicine Southern Medical University Guangzhou China.
  4. 4Department of Traditional Chinese Medicine Dermatology Dermatology Hospital Southern Medical University Guangzhou China.
  5. 5Dermatology Hospital Institute of Dermatology and Venereology Southern Medical University Guangzhou China.
  6. 6Evaluation Center for Skin Care Product Efficacy Dermatology Hospital Southern Medical University Guangzhou China.
  7. 7Medical Affairs Sanofi Shanghai China.
  8. 8Medical Affairs Sanofi Beijing China.
  9. 9Medical Affairs Sanofi Guangzhou China.
  10. 10Department of Dermatology Second Xiangya Hospital Central South University Changsha China.
Read full textPDFDOICite

Abstract

Dupilumab improves skin barrier function in patients with atopic dermatitis (AD), but data for Chinese patients are limited. This 16-week, prospective, exploratory study investigated the impact of dupilumab on skin barrier function in Chinese patients with moderate-to-severe AD. Forty-four participants (24 patients with AD and 20 healthy volunteers) were enrolled. Patients with AD received dupilumab treatment every 2 weeks and were followed up to Week 16. Tape-stripped stratum corneum samples were collected from participants at seven specific time points for proteomic and lipidomic profiling, together with transepidermal water loss (TEWL) measurement. At Week 16, TEWL after five tape strips was significantly reduced versus baseline (adjusted p = 0.0006). Proteomics revealed significant upregulation of sphingolipid and other lipid metabolism pathways within the first 2 weeks, coinciding with early TEWL improvement; keratinocyte differentiation and keratinization pathways were enriched from Week 8 through Week 16. Lipidomics revealed that specific dysregulated ceramides-CER(d16:0/16:0), CER(d16:0/20:3), CER(t20:1/23:0), and CER(t20:1/24:1)-showed significant changes by Weeks 2-8 and completely normalized by Week 16. Dupilumab improved skin barrier function in Chinese patients with moderate-to-severe AD, accompanied by dynamic molecular changes; these correlative findings require functional validation to establish causality. Trial Registration: ClinicalTrials.gov NCT05624112.

Related

  1. Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison
    April Armstrong, Leon Kircik, Andrei Metelitsa +9
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCDOAJ
  2. Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders.
    Li Ma, Mengjun Wei, Wenjia Mou +6
    BMC pediatricsPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMCDOAJ
  3. Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study
    Marley Cutrona, Alexandra K. Golant
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCDOAJ
  4. Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
    Peng Yu, Fenglei Wei
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study.
    Elena Pezzolo, Maddalena Napolitano, Martina Maurelli +12
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{liu2026impact,
  title = {{Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate-to-Severe Atopic Dermatitis: A Phase IV, Non-Randomized, Open-Label, Parallel-Group Clinical Study.}},
  author = {Taoming Liu and Shuting Chen and Weijia Zhao and Dake Di and Jiao Liu and Yuyang Tian and Yurong Luo and Yingping Xu and Ruzeng Xue and Li Ye and Xiaoping Pei and Bihui Yu and Yu Wang and Jiao Zhang and Xiaoling Yu and Wei Wen and Liyan Yuan and Suyun Ji and Claire Hu and Dan Shen and Yiqing Guo and Yunsheng Liang},
  journal = {MedComm},
  year = {2026},
  month = oct,
  doi = {10.1002/mco2.71091},
  url = {https://europepmc.org/article/MED/42928785},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate-to-Severe Atopic Dermatitis: A Phase IV, Non-Randomized, Open-Label, Parallel-Group Clinical Study.
AU  - Taoming Liu
AU  - Shuting Chen
AU  - Weijia Zhao
AU  - Dake Di
AU  - Jiao Liu
AU  - Yuyang Tian
AU  - Yurong Luo
AU  - Yingping Xu
AU  - Ruzeng Xue
AU  - Li Ye
AU  - Xiaoping Pei
AU  - Bihui Yu
AU  - Yu Wang
AU  - Jiao Zhang
AU  - Xiaoling Yu
AU  - Wei Wen
AU  - Liyan Yuan
AU  - Suyun Ji
AU  - Claire Hu
AU  - Dan Shen
AU  - Yiqing Guo
AU  - Yunsheng Liang
PY  - 2026
DA  - 2026/10/25
JO  - MedComm
DO  - 10.1002/mco2.71091
UR  - https://europepmc.org/article/MED/42928785
AB  - Dupilumab improves skin barrier function in patients with atopic dermatitis (AD), but data for Chinese patients are limited. This 16-week, prospective, exploratory study investigated the impact of dupilumab on skin barrier function in Chinese patients with moderate-to-severe AD. Forty-four participants (24 patients with AD and 20 healthy volunteers) were enrolled. Patients with AD received dupilumab treatment every 2 weeks and were followed up to Week 16. Tape-stripped stratum corneum samples were collected from participants at seven specific time points for proteomic and lipidomic profiling, together with transepidermal water loss (TEWL) measurement. At Week 16, TEWL after five tape strips was significantly reduced versus baseline (adjusted p = 0.0006). Proteomics revealed significant upregulation of sphingolipid and other lipid metabolism pathways within the first 2 weeks, coinciding with early TEWL improvement; keratinocyte differentiation and keratinization pathways were enriched from Week 8 through Week 16. Lipidomics revealed that specific dysregulated ceramides-CER(d16:0/16:0), CER(d16:0/20:3), CER(t20:1/23:0), and CER(t20:1/24:1)-showed significant changes by Weeks 2-8 and completely normalized by Week 16. Dupilumab improved skin barrier function in Chinese patients with moderate-to-severe AD, accompanied by dynamic molecular changes; these correlative findings require functional validation to establish causality. Trial Registration: ClinicalTrials.gov NCT05624112.
SN  - 2688-2663
ER  -